RDY
Dr. Reddy's Laboratories Limited$13.30
LiveJun 12, 2026
Market cap
$11.07B
52w range
12.19 – 15.89
P / E
—
EPS · FY 2026
$53.92
Volume
1.01M
Revenue · FY 2026
$353.47B
Explain this page
Arphra AIPlain-English read on Dr. Reddy's Laboratories Limited’s valuation06-13today
- Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States12h
- Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States12h
- Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript32d
- Indian drugmaker Dr Reddy's posts quarterly profit slump32d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$160.34
+1105.56% vs spot
Recommendation
Strong Buy
19 of 20 methods
Method spread
6bull13bear
±5% threshold
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.45% | +0.61% | +2.39% | -5.87% | -5.14% | -5.27% | -15.82% | +15.05% | -10.38% | +45.67% | +1216.83% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$13.56
1 sh
Bid
$13.00
104 sh
Ask
$14.16
1 sh
Spread
$1.160
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United Statesbusinesswire.com·Jun 13, 2026
- Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United Statesbusinesswire.com·Jun 13, 2026
- Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcriptseekingalpha.com·May 12, 2026
- Indian drugmaker Dr Reddy's posts quarterly profit slumpreuters.com·May 12, 2026
Peers
No peer list available for RDY.
Total assets
$567.88B
Total debt
$75.81B
Cash & equiv
$15.06B
Operating CF
$56.65B
Free cash flow
$32.1B
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2026 | $353.47B | $48.87B | $45.09B | $53.92 | +12.76% |